[Comment] Combination therapies for patients with metastatic renal cell carcinoma

In the past decade, several single drugs have been approved for the treatment of metastatic renal cell carcinoma, with substantial benefits in disease control, resolution of symptoms, and survival for the patients.1 In the meantime, only two combination therapies, bevacizumab plus interferon-alfa as first-line treatment and lenvatinib plus everolimus in the second-line setting, have been approved on the basis of a better outcome and an acceptable toxicity over single drugs.2,3 The poor tolerability and absence of predictive biomarkers for treatment response represented major issues in the development of combination strategies.

Source: The Lancet Oncology - February 10, 2018 Category: Cancer & Oncology Authors: Giuseppe Procopio, Raffaele Ratta, Filippo de Braud, Elena Verzoni Tags: Comment Source Type: research